February 2019 was a busy month for biosimilars on the policy front, with pharmaceutical executives called to testify before law makers and industry attempting to navigate a raft of proposed Trump administration policies aimed at reducing the cost of drugs.
February 2019 was a busy month for biosimilars on the policy front, with pharma executives called to testify before law makers and industry attempting to navigate a raft of proposed Trump administration policies aimed at reducing the cost of drugs.
The month kicked off with an HHS proposed rule to block rebates and discounts given to pharmacy benefit managers (PBMs), Medicare Part D plans, and Medicaid managed care organizations by ending safe harbor protections that currently shelter drug makers’ rebates from penalties under the federal Anti-Kickback Statute. The rule would also create new safe harbor for discounts offered to patients.
The rule has substantial implications for the biosimilars market, where rebates have allegedly played a role in stymying biosimilar competition. According to allegations brought by Pfizer against Johnson & Johnson (J&J) in an ongoing antitrust lawsuit, Remicade-maker J&J used the so-called “rebate trap” to block competition from infliximab biosimilars in the United States. (Canadian officials this month, however, said that they had found “insufficient evidence” that J&J’s conduct in the Canadian market had substantially impacted biosimilars’ ability to compete.)
Response to the proposed rule on rebates was mixed; drug makers represented by the Pharmaceutical Research and Manufacturers of America, known as PhRMA, and the Association for Accessible Medicines praised the rule’s attempt to address misaligned incentives that lead to higher list prices, and provider group the Community Oncology Alliance called the plan “extremely good news for patients.” However, the Pharmaceutical Care Management Association, which represents PBMs, said the rule would lead to higher out-of-pocket spending, and the Academy of Managed Care Pharmacy called the plan’s aims “unrealistic.”
Drug makers continued to call the current rebate system into question during a full committee hearing before the US Senate Committee on Finance near the end of the month. In his testimony, Pascal Soriot, executive director and chief executive officer (CEO) of AstraZeneca, called the current system of rebates unsustainable. He said the United States should move away from the rebate system, but if that proves to be impossible, it should dedicate a portion of discounts and rebates to instituting caps on out-of-pocket spending for patients.
Albert Bourla, DVM, PhD, CEO of Pfizer, added that he supports passing all rebates to patients. Currently, the rebates are “swallowed up by the supply chain,” he said, agreeing on the need to cap seniors’ out-of-pocket costs. Both Bourla and Soriot called on Congress to “knock down barriers” to biosimilars as another means by which to reduce the cost of drugs.
Several of the drug makers who testified also voiced concern about another of the Trump administration’s proposed policies: the International Pricing Index (IPI), which would which would link drug prices in the United States to prices paid in other countries. Olivier Brandicourt, MD, CEO of Sanofi, warned that using the model would be “outsourcing price decisions” to overseas players, and Jennifer Taubert, executive vice president and worldwide chairman of J&J’s Janssen, added that she sees a need for an “American solution to an American challenge.”
As the United States considers implementing the model, stakeholders are beginning to pay closer attention to how drugs are priced in the nations the United States may use as benchmarks. The German system, for one, is the subject of a recent issue brief that outlines a system under which drugs that offer incremental benefits are subject to price negotiation between pharma and a single umbrella organization of health plans. The brief’s authors suggest that the German model offers an alternative to the US system and its especially high burden on patients.
Other European nations had successes with price negotiation this month; the United Kingdom’s National Institute for Health and Care Excellence (NICE) recommended pertuzumab (Perjeta) for use in patients with HER2-positive early breast cancer who have lymph node—positive disease. The recommendation was a breakthrough after previous rejections of the drug for routine use based on its high cost. According to NICE, Roche offered a confidential price reduction on pertuzumab, and biosimilar trastuzumab added cost savings that brought the therapy within an acceptable cost threshold.
Among other Trump administration proposals to rein in drug pricing is a potential requirement for drug makers to include list prices in direct-to-consumer advertising, and some drug makers are launching ads with list prices ahead of such a requirement. J&J this month announced that it will begin including list prices and potential out-of-pocket costs in its ads during the first quarter of 2019.
However, some research suggests that adding list prices to ads may not impact consumer behavior with respect to high-cost drugs; a study published this month found that the inclusion of statements that a patient could have a low out-of-pocket cost for a high-priced drug mitigated reluctance to discuss such a drug with a provider.
Finally, insulin, a therapy that is a continual focal point of criticism about drug costs given repeated price hikes, will be the subject of a bipartisan probe by the Senate Finance Committee. Senators are seeking details about pricing, research and development costs, rebates, PBM pacts, patient assistance programs, donations to patient advocacy groups, production, marketing and advertising, revenues and gross margins from selling insulin, and the companies’ funding of patient assistance programs.
Meanwhile, a proposed class-action lawsuit against 3 major insulin makers was allowed to proceed this month. While a judge threw out racketeering claims in the lawsuit against Novo Nordisk, Eli Lilly, and Sanofi, the court will allow the case, which argues that drug makers artificially inflate drugs’ list prices to placate PBMs, to move forward, denying the drug makers’ requests to dismiss the suit.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.